Literature DB >> 9586584

A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells.

O Kaminuma1, K Ogawa, H Kikkawa, M Kikuchi, K Naito, K Ikezawa.   

Abstract

The effect of a novel anti-allergic drug, betotastine besilate (betotastine) on interleukin (IL)-5 production by human peripheral blood mononuclear cells (PBMC) was investigated. PBMC of Dermatophagoides farinae extract (Df)-sensitive donors produced IL-5 and showed a proliferative response upon stimulation with relevant antigen (10 microg/ml). Df-induced IL-5 production by PBMC was significantly inhibited by betotastine at 10 and 100 microM. Betotastine also suppressed proliferation of PBMC with less potency. The effect of betotastine on IL-5 production was enhanced and significant even at 0.1 microM when the drug was added 120 min before antigen stimulation. Ketotifen and cetirizine also inhibited IL-5 production, but the effects of these drugs were significant only at 100 microM. These findings indicate that the suppression of IL-5 production may be involved in the anti-allergic effect of betotastine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9586584     DOI: 10.1248/bpb.21.411

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

Review 1.  Oral bepotastine: in allergic disorders.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

2.  Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure.

Authors:  Sho Kanzaki; Kazuhiro Hashiguchi; Ken-Ichiro Wakabayashi; Kiyochika Suematsu; Kimihiro Okubo
Journal:  J Drug Assess       Date:  2016-09-27

3.  An Investigator-Blind Randomized Controlled Trial Comparing Effectiveness, Safety of Levocetirizine and Bepotastine in Chronic Urticaria.

Authors:  Amrita Sil; Sufiur Rahaman; Nasiruddin Mondal; Sk Shahriar Ahmed; Dhiman Tarafdar; Aparesh Chandra Patra; Sudipta Roy; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.